Beyond morphology: Minimal residual disease detection in acute myeloid leukemia

Current Opinion in Hematology

Volumn 19, Issue 2, 2012, Pages 82-88

  Dinardo, Courtney D ^a   Luger, Selina M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

acute myeloid leukemia; leukemia associated immunophenotype; minimal residual disease; multiparameter flow cytometry; Wilms' tumor gene

Indexed keywords

CYTARABINE; DAUNORUBICIN; DENDRITIC CELL VACCINE; DNA METHYLTRANSFERASE INHIBITOR; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; MESSENGER RNA; TRANSCRIPTION FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADD ON THERAPY; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CYTOGENETICS; DRUG DOSE COMPARISON; DRUG MEGADOSE; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; LABORATORY DIAGNOSIS; LOW DRUG DOSE; MEDICAL DECISION MAKING; MINIMAL RESIDUAL DISEASE; NEPHROBLASTOMA; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME; WILM TUMOR GENE;

FLOW CYTOMETRY; GENES, WILMS TUMOR; HUMANS; LEUKEMIA, MYELOID, ACUTE; NEOPLASM PROTEINS; NEOPLASM, RESIDUAL; REAL-TIME POLYMERASE CHAIN REACTION; RECURRENCE; TUMOR MARKERS, BIOLOGICAL;

EID: 84856889380     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3283501325     Document Type: Review

References (34)

1. Fenaux P, Preudhomme C, Lai JL, et al. Cytogenetics and their prognostic value in de novo acutemyeloid leukaemia: A report on283cases. Br JHaematol 1989; 73:61-67. (Pubitemid 19237737)
2. Keating MJ, Smith TL, Kantarjian H, et al. Cytogenetic pattern in acute myelogenous leukemia: A major reproducible determinant of outcome. Leukemia 1988; 2:403-412.
3. Bacher U, Haferlach T, Fehse B, et al. Minimal residual disease diagnostics and chimerism in the posttransplant period in acute myeloid leukemia. Sci World J 2011; 11:310-319.
4. Campana D. Progress of minimal residual disease studies in childhood acute leukemia. Curr Hematol Malig Rep 2010; 5:169-176.
5. Shook D, Coustan-Smith E, Ribeiro RC, et al. Minimal residual disease quantitation in acute myeloid leukemia. Clin Lymphoma Myeloma 2009; 9 (Suppl 3):S281-S285.
6. Santamaria C, Chillon MC, Fernandez C, et al. Using quantification of the PML-RARalpha transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia. Haematologica 2007; 92:315-322. (Pubitemid 350143540)
7. Grimwade D, Jovanovic JV, Hills RK, et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct preemptive arsenic trioxide therapy. J Clin Oncol 2009; 27:3650-3658.
8. Corbacioglu A, Scholl C, Schlenk RF, et al. Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia. J Clin Oncol 2010; 28:3724-3729. One of the largest cohorts of AML with inv(16) to date. This study identified that persistently negative fusion transcripts via MRDmonitoring during consolidation and early follow-up identified a cohort of patients with significantly improvedRFSand OS.
9. Marcucci G, Caligiuri MA, Dohner H, et al. Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia. Leukemia 2001; 15:1072-1080. (Pubitemid 32717277)
10. Guieze R, Renneville A, Cayuela JM, et al. Prognostic value of minimal residual disease by real-time quantitative PCR in acute myeloid leukemia with CBFBMYH11 rearrangement: The French experience. Leukemia 2010; 24:1386-1388.
11. Perea G, Lasa A, Aventin A, et al. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16). Leukemia 2006; 20:87-94.
12. Scholl C, Schlenk RF, Eiwen K, et al. The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia. Haematologica 2005; 90:1626-1634. (Pubitemid 41814986)
13. Kronke J, Schlenk RF, Jensen KO, et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: A study from the German-Austrian Acute Myeloid Leukemia Study Group. J Clin Oncol 2011; 29:2709-2716. MRD detection of NPM1 mutations at induction and consolidation periods led to dramatically different odds of relapse and significantly different OS. See figure in this review for depiction of CIR and OS for patients in complete remission according to MRD status after induction therapy in bone marrow (negative vs. any positive NPM1 mutation transcript level value).
14. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352: 254-266. (Pubitemid 40110814)
15. Schnittger S, Schoch C, Kern W, et al. FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia. Acta Haematol 2004; 112 (1-2):68-78. (Pubitemid 38716251)
16. Cloos J, Goemans BF, Hess CJ, et al. Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia 2006; 20:1217-1220. (Pubitemid 43905824)
17. Chou WC, Hou HA, Liu CY, et al. Sensitive measurement of quantity dynamics of FLT3 internal tandem duplication at early time points provides prognostic information. Ann Oncol 2011; 22:696-704. The role of FLT3-ITD for MRD monitoring is evaluated.
18. Ostergaard M, Nyvold CG, Jovanovic JV, et al. Development of standardized approaches to reporting of minimal residual disease data using a reporting software package designed within the European LeukemiaNet. Leukemia 2011; 25:1168-1173. The European LeukemiaNet MRD-reporting software program is detailed here, which provides efficient handling of RQ-PCR data from various individualized RQPCR platforms into uniform and intuitive reports.
19. van der Velden VH, van der Sluijs-Geling A, Gibson BE, et al. Clinical significance of flow cytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/ MRC AML12 protocol. Leukemia 2010; 24:1599-1606.
20. Kern W, Bacher U, Haferlach C, et al. The role of multiparameter flow cytometry for disease monitoring in AML. Best Pract Res Clin Haematol 2010; 23:379-390.
21. Venditti A, Buccisano F, Del Poeta G, et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 2000; 96:3948-3952.
22. Buccisano F, Maurillo L, Gattei V, et al. The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. Leukemia 2006; 20:1783-1789. (Pubitemid 44590961)
23. Buccisano F, Maurillo L, Spagnoli A, et al. Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. Blood 2010; 116:2295-2303. The incorporation of MRD status into risk-stratification led to two distinct categories of risk for AML patients, with significant prognostic relevance.
24. Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: Results of the AML02 multicentre trial. Lancet Oncol 2010; 11:543-552. A risk-Adapted treatment approach, incorporating MRD status after treatment, is performed in this pediatric AML trial, and a marked improvement in outcomes compared to historical pediatric AML trials is noted.
25. Rubnitz JE, Crews KR, Pounds S, et al. Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: Results of the St Jude AML97 trial. Leukemia 2009; 23:1410-1416.
26. Lange BJ, Smith FO, Feusner J, et al. Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: A report from the children's oncology group. Blood 2008; 111: 1044-1053. (Pubitemid 351213382)
27. Gibson BE, Wheatley K, Hann IM, et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 2005; 19:2130-2138. (Pubitemid 41741605)
28. Borowitz MJ, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: A Children's Oncology Group study. Blood 2008; 111:5477-5485.
29. Kroger N, Bacher U, Bader P, et al. NCI First InternationalWorkshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes. Biol Blood Marrow Transplant 2010; 16: 1187-1211.
30. Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: A European LeukemiaNet study. J Clin Oncol 2009; 27:5195-5201.
31. Candoni A, Toffoletti E, Gallina R, et al. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia. Clin Transplant 2011; 25:308-316. This study identifies that WT1 transcript levels can independently predict relapse in the posttransplant setting, prior to overt morphologic relapse.
32. Van Tendeloo VF, Van de Velde A, Van Driessche A, et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A 2010; 107:13824-13829. A preliminary study (phase I/II trial) utilizing WT1 antigen-targeted autologous dendritic cell vaccination to achieve longitudinal control of AML MRD is performed with encouraging results.
33. Kroger N, Miyamura K, Bishop MR. Minimal residual disease following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011; 17 (1 Suppl):S94-S100.
34. Walter RB, Gooley TA, Wood BL, et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol 2011; 29:1190-1197. A review of patients receiving myeloablative transplants for AML in first morphologic remission revealed that approximately one of four of patients had evidence of MRD prior to transplant, with statistically significant differences in OS in the MRD-positive vs. MRD-negative subgroups.